2-methoxy-N-pentylacetamide | 951776-93-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-methoxy-N-pentylacetamide
• CAS: 951776-93-5
• 化学式: C₈H₁₇NO₂
• mdl: MFCD20355090
• 分子量: 159.228
• InChiKey: YSBLNCKFTUMGAZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION<br/>[FR] DÉGRONIMÈRES HÉTÉROCYCLIQUES POUR LA DÉGRADATION DE PROTÉINES CIBLES
  申请人：C4 THERAPEUTICS INC

  公开号：WO2017197055A1

  公开（公告）日：2017-11-16

  This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) ("Degrons"), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.

  这项发明提供了结合到E3泛素连接酶（通常通过cereblon）的杂环化合物（“Degrons”），可以直接使用，也可以与靶向配体连接到选择的靶蛋白上，用于治疗目的，以及它们的使用方法、组合物以及制备方法。
• [EN] TARGETED PROTEIN DEGRADATION<br/>[FR] DÉGRADATION CIBLÉE DE PROTÉINES
  申请人：C4 THERAPEUTICS INC

  公开号：WO2020132561A1

  公开（公告）日：2020-06-25

  This invention provides pharmaceutical protein degraders and E3 ubiquitin ligase binders for therapeutic applications as described further herein.

  这项发明提供了用于治疗应用的药用蛋白质降解剂和E3泛素连接酶结合物。
• PROCESS FOR PREPARING AMIDES FROM ALCOHOLS AND AMINES
  申请人：MILSTEIN David

  公开号：US20090112005A1

  公开（公告）日：2009-04-30

  The present invention provides a process for preparing amides, by reacting a primary amine and a primary alcohol in the presence of a Ruthenium catalyst, to generate the amide and molecular hydrogen. According to the process of the invention, primary amines are directly acylated by equimolar amounts of alcohols to produce amides and molecular hydrogen (the only byproduct) in high yields and high turnover numbers. This reaction is catalyzed by a Ruthenium complex, which is preferably based on a dearomatized PNN-type ligand of formula A1 or precursors thereof of formulae A2 or A3. Use of diamines in the reaction leads to bis-amides, whereas with a mixed primary/secondary amine substrate, chemoselective acylation of the primary amine group occurs.

  本发明提供了一种制备酰胺的方法，通过在Ruthenium催化剂的存在下反应一种一级胺和一种一级醇，生成酰胺和分子氢。根据本发明的方法，一级胺通过等摩尔量的醇直接酰化产生酰胺和分子氢（唯一的副产物），产率高，周转数高。这种反应由Ruthenium配合物催化，最好是基于公式A1的去芳香PNN型配体或其前体公式A2或A3。在反应中使用二胺会导致双酰胺，而使用混合的一级/二级胺底物，会发生一级胺基的化学选择性酰化。
• USE OF RUTHENIUM COMPLEXES FOR FORMATION AND/OR HYDROGENATION OF AMIDES AND RELATED CARBOXYLIC ACID DERIVATIVES
  申请人：Milstein David

  公开号：US20120253042A1

  公开（公告）日：2012-10-04

  A process for preparing amides by reacting a primary amine and a primary alcohol in the presence of a Ruthenium complex to generate the amide and molecular hydrogen. Primary amines are directly acylated by equimolar amounts of alcohols to produce amides and molecular hydrogen (the only byproduct) in high yields and high turnover numbers. Also disclosed are processes for hydrogenation of amides to alcohols and amines; hydrogenation of organic carbonates to alcohols; hydrogenation of carbamates or urea derivatives to alcohols and amines; amidation of esters; acylation of alcohols using esters; coupling of alcohols with water and a base to form carboxylic acids; dehydrogenation of beta-amino alcohols to form pyrazines and cyclic dipeptides; and dehydrogenation of secondary alcohols to ketones. These reactions are catalyzed by a Ruthenium complex which is based on a dearomatized PNN-type ligand of formula A1 or precursors thereof of formulae A2 or A3.

  一种制备酰胺的方法，包括在Ruthenium配合物的存在下，通过反应一种一级胺和一种一级醇生成酰胺和分子氢。直接用等摩尔量的醇对一级胺进行酰化反应，可以高产率、高周转数地生成酰胺和分子氢（唯一的副产物）。此外，还揭示了将酰胺氢化为醇和胺的方法；将有机碳酸酯氢化为醇的方法；将氨基甲酸酯或尿素衍生物氢化为醇和胺的方法；酯的酰胺化反应；使用酯对醇进行酰化反应；将醇与水和碱偶联形成羧酸；将β-氨基醇脱氢生成吡嗪和环肽；以及将二级醇脱氢生成酮的方法。这些反应由基于A1式或A2式或A3式的去芳香的PNN型配体的Ruthenium配合物催化。
• [EN] THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF<br/>[FR] AGENTS THÉRAPEUTIQUES POUR LA DÉGRADATION DE BRAF MUTANTE
  申请人：C4 THERAPEUTICS INC

  公开号：WO2022261250A1

  公开（公告）日：2022-12-15

  The present invention provides compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions that can be administered to a host such as a human in need thereof for the treatment of a disorder, such as cancer, mediated by mutant BRAF. The compounds efficiently degrade Class I, II and III mutant BRAF proteins.

  本发明提供了化合物或其药学上可接受的盐类及其药物组合物，这些化合物或其药学上可接受的盐类及其药物组合物可施用给需要的宿主（如人类），用于治疗由突变 BRAF 介导的疾病（如癌症）。这些化合物能有效降解 I、II 和 III 类突变 BRAF 蛋白。